127 related articles for article (PubMed ID: 28234741)
1. Concomitant Use of Panobinostat and Reirradiation in Progressive DIPG: Report of 2 Cases.
Wang ZJ; Ge Y; Altinok D; Poulik J; Sood S; Taub JW; Edwards H; Kieran MW; Steven M
J Pediatr Hematol Oncol; 2017 Aug; 39(6):e332-e335. PubMed ID: 28234741
[TBL] [Abstract][Full Text] [Related]
2. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.
Hennika T; Hu G; Olaciregui NG; Barton KL; Ehteda A; Chitranjan A; Chang C; Gifford AJ; Tsoli M; Ziegler DS; Carcaboso AM; Becher OJ
PLoS One; 2017; 12(1):e0169485. PubMed ID: 28052119
[TBL] [Abstract][Full Text] [Related]
3. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.
Grasso CS; Tang Y; Truffaux N; Berlow NE; Liu L; Debily MA; Quist MJ; Davis LE; Huang EC; Woo PJ; Ponnuswami A; Chen S; Johung TB; Sun W; Kogiso M; Du Y; Qi L; Huang Y; Hütt-Cabezas M; Warren KE; Le Dret L; Meltzer PS; Mao H; Quezado M; van Vuurden DG; Abraham J; Fouladi M; Svalina MN; Wang N; Hawkins C; Nazarian J; Alonso MM; Raabe EH; Hulleman E; Spellman PT; Li XN; Keller C; Pal R; Grill J; Monje M
Nat Med; 2015 Jun; 21(6):555-9. PubMed ID: 25939062
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).
Monje M; Cooney T; Glod J; Huang J; Peer CJ; Faury D; Baxter P; Kramer K; Lenzen A; Robison NJ; Kilburn L; Vinitsky A; Figg WD; Jabado N; Fouladi M; Fangusaro J; Onar-Thomas A; Dunkel IJ; Warren KE
Neuro Oncol; 2023 Dec; 25(12):2262-2272. PubMed ID: 37526549
[TBL] [Abstract][Full Text] [Related]
5. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
[TBL] [Abstract][Full Text] [Related]
6. Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature.
Freese C; Takiar V; Fouladi M; DeWire M; Breneman J; Pater L
Pract Radiat Oncol; 2017; 7(2):86-92. PubMed ID: 28274399
[TBL] [Abstract][Full Text] [Related]
7. Panobinostat active against diffuse intrinsic pontine glioma.
Bagcchi S
Lancet Oncol; 2015 Jun; 16(6):e267. PubMed ID: 25971867
[No Abstract] [Full Text] [Related]
8. Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience.
Lassaletta A; Strother D; Laperriere N; Hukin J; Vanan MI; Goddard K; Lafay-Cousin L; Johnston DL; Zelcer S; Zapotocky M; Rajagopal R; Ramaswamy V; Hawkins C; Tabori U; Huang A; Bartels U; Bouffet E
Pediatr Blood Cancer; 2018 Jun; 65(6):e26988. PubMed ID: 29369515
[TBL] [Abstract][Full Text] [Related]
9. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience.
Kline C; Liu SJ; Duriseti S; Banerjee A; Nicolaides T; Raber S; Gupta N; Haas-Kogan D; Braunstein S; Mueller S
J Neurooncol; 2018 Dec; 140(3):629-638. PubMed ID: 30206764
[TBL] [Abstract][Full Text] [Related]
10. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group.
Janssens GO; Gandola L; Bolle S; Mandeville H; Ramos-Albiac M; van Beek K; Benghiat H; Hoeben B; Morales La Madrid A; Kortmann RD; Hargrave D; Menten J; Pecori E; Biassoni V; von Bueren AO; van Vuurden DG; Massimino M; Sturm D; Peters M; Kramm CM
Eur J Cancer; 2017 Mar; 73():38-47. PubMed ID: 28161497
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
Thomas S; Aggarwal R; Jahan T; Ryan C; Troung T; Cripps AM; Raha P; Thurn KT; Chen S; Grabowsky JA; Park J; Hwang J; Daud A; Munster PN
Ann Oncol; 2016 May; 27(5):947-52. PubMed ID: 26903311
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
Rathkopf D; Wong BY; Ross RW; Anand A; Tanaka E; Woo MM; Hu J; Dzik-Jurasz A; Yang W; Scher HI
Cancer Chemother Pharmacol; 2010 May; 66(1):181-9. PubMed ID: 20217089
[TBL] [Abstract][Full Text] [Related]
13. Second re-irradiation for DIPG progression, re-considering "old strategies" with new approaches.
Morales La Madrid A; Santa-María V; Cruz Martinez O; Mora J; Puerta Roldan P; Guillen Quesada A; Suñol Capella M; de Torres Gomez-Pallete C; Lassaletta A; Laperriere N; Villà S; Bouffet E
Childs Nerv Syst; 2017 May; 33(5):849-852. PubMed ID: 28251325
[TBL] [Abstract][Full Text] [Related]
14. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
Berenson JR; Hilger JD; Yellin O; Boccia RV; Matous J; Dressler K; Ghazal HH; Jamshed S; Kingsley EC; Harb WA; Noga SJ; Nassir Y; Swift RA; Vescio R
Ann Hematol; 2014 Jan; 93(1):89-98. PubMed ID: 24135804
[TBL] [Abstract][Full Text] [Related]
15. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
16. Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy.
Shan S; Chen J; Sun Y; Wang Y; Xia B; Tan H; Pan C; Gu G; Zhong J; Qing G; Zhang Y; Wang J; Wang Y; Wang Y; Zuo P; Xu C; Li F; Guo W; Xu L; Chen M; Fan Y; Zhang L; Liang XJ
Adv Sci (Weinh); 2022 Jul; 9(21):e2200353. PubMed ID: 35585670
[TBL] [Abstract][Full Text] [Related]
17. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
San-Miguel JF; Hungria VTM; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Na Nakorn T; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Salwender H; Sopala M; Redhu S; Paul S; Corrado C; Richardson PG
Br J Haematol; 2017 Oct; 179(1):66-74. PubMed ID: 28653400
[TBL] [Abstract][Full Text] [Related]
18. Single institution experience in re-irradiation of biopsy-proven diffuse intrinsic pontine gliomas.
Zamora PL; Miller SR; Kovoor JJ
Childs Nerv Syst; 2021 Aug; 37(8):2539-2543. PubMed ID: 33973056
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas.
Shi W; Palmer JD; Werner-Wasik M; Andrews DW; Evans JJ; Glass J; Kim L; Bar-Ad V; Judy K; Farrell C; Simone N; Liu H; Dicker AP; Lawrence YR
J Neurooncol; 2016 May; 127(3):535-9. PubMed ID: 26821711
[TBL] [Abstract][Full Text] [Related]
20. Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model.
Singleton WG; Collins AM; Bienemann AS; Killick-Cole CL; Haynes HR; Asby DJ; Butts CP; Wyatt MJ; Barua NU; Gill SS
Int J Nanomedicine; 2017; 12():1385-1399. PubMed ID: 28260886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
